Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorphenoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.57 |
| ▸ | HTR1A | P08908 | 3/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.57 |
| ▸ | DRD1 | P21728 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorphenoxamine SCHEMBL125112 | 0.98 | CHRM2 (0.59) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 | |
| Chlorphenoxamine SCHEMBL1649036 | 0.97 | CHRM2 (0.62) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 | |
| Moxastine SCHEMBL29281 | 0.90 | CHRM2 (0.71) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 | |
| Chlorphenoxamine SCHEMBL13723924 | 0.88 | CHRM2 (0.61) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 | |
| Clofenetamine SCHEMBL2110100 | 0.85 | CHRM2 (0.54) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 | |
| Embramine SCHEMBL28365 | 0.84 | CHRM2 (0.61) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 | |
| Clofenetamine SCHEMBL4422383 | 0.84 | CHRM2 (0.53) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 | |
| Embramine SCHEMBL1650532 | 0.83 | CHRM2 (0.59) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2738809 | 0.82 | CHRM2 (0.49) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10733508 | 0.82 | CHRM2 (0.61) | CHRM2KCNH2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| WO-2024229174-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| US-20220257780-A1 | MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF | BRILLIAN PHARMA INC. (US) | 2022-08-18 | — | — | US | claimed |
| EP-4041309-A1 | MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF | Brillian Pharma Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| WO-2021071902-A1 | MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF | BRILLIAN PHARMA INC. (US) | 2021-04-15 | — | — | WO | claimed |
| US-20030099711-A1 | Sustained release preparations | LAURUS MASTER FUND, LTD. | 2003-05-29 | — | — | US | claimed |
| US-20020151541-A1 | For treatment of respiratory tract diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | claimed |
| WO-2002015700-A1 | PRODRUGS ACTIVATED BY PLASMIN AND THEIR USE IN CANCER CHEMOTHERAPY | COULTER PHARMACEUTICAL, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0665749-B1 | COMPOSITION FOR THE TREATMENT OF PARKINSON'S DISEASE | KAMINSKI RAM (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0367746-B1 | Sustained release drug-resin complexes | RICHARDSON VICKS INC (US) | 1994-02-02 | — | — | EP | claimed |
| US-4996047-A | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1991-02-26 | — | — | US | claimed |
| EP-0367746-A2 | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1990-05-09 | — | — | EP | claimed |